Article
Cell Biology
Yuan Xiang, Hui Liu, Hao Hu, Le-Wei Li, Qi-Bei Zong, Tang-Wei Wu, Xiao-Yi Li, Shi-Qiang Fang, Yi-Wen Liu, Yu Zhan, Hui Wang, Zhong-Xin Lu
Summary: This study has identified a new mechanism of Letrozole sensitivity in ER positive breast cancer. By regulating the expression of noncoding RNA LINC00094 and miR-19a-3p, the migration and EMT process of breast cancer cells can be influenced, ultimately improving the sensitivity of breast cancer to Letrozole.
Article
Medicine, General & Internal
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice Andre, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O'Shaughnessy
Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Jankiben R. Patel, Karen M. Gallegos, Rashidra R. Walker, A. Michael Davidson, Ian Davenport, Syreeta L. Tilghman
Summary: The study evaluated the contribution of mammospheres in letrozole-resistant breast cancer, finding that LTLT-Ca tumors expressed CD44(+)/CD24(+) markers, while AC-1 tumors had lower CD44/CD24 expression.
Article
Oncology
Hope S. Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman, Adam Brufsky
Summary: This study compared the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in older patients with HR+/HER2-MBC in US clinical practice. The results showed that palbociclib plus letrozole significantly improved progression-free survival, overall survival, and tumor responses compared to letrozole alone.
Article
Multidisciplinary Sciences
Gurusamy Umamaheswaran, Dharanipragada Kadambari, Suresh Kumar Muthuvel, Naveena A. N. Kumar, Biswajit Dubashi, Steven Aibor Dkhar, Chandrasekaran Adithan
Summary: The study investigated the association between TCL1A gene polymorphisms with letrozole-induced adverse events in South Indian HR+ breast cancer patients. The findings revealed no significant genetic association between TCL1A gene variants and adverse events caused by letrozole. Although common side effects were observed, genetic variants in TCL1A gene may not play a significant role in predicting letrozole-induced adverse events in this specific population.
Article
Oncology
Zhi-yuan Pang, Yun-tao Wei, Mu-yan Shang, Shuang Li, Yang Li, Quan-xiu Jin, Zhi-xuan Liao, Ming-ke Cui, Xiao-yan Liu, Qiang Zhang
Summary: The study reveals that PBX3 gene is significantly upregulated in letrozole-resistant breast cancer cells and tissues, correlating to poorer progression-free survival in patients. Further experiments demonstrate that PBX3 weakens response to letrozole by promoting BCa cell survival and anchorage-independent growth, and confers letrozole resistance via transactivation of the FGFR1 signaling pathway. This molecular event must coordinate a synergistic transcription activation programs through interacting with MTA1-HDAC2 complex.
ENDOCRINE-RELATED CANCER
(2021)
Review
Cell Biology
Farbod Bahreini, Elham Rayzan, Nima Rezaei
Summary: Breast cancer, a multifactorial disease, may have an increased risk due to alterations in microRNA sequences. miR-SNPs are potential biomarkers for early detection of breast cancer.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Review
Pathology
Esmat Abdi, Saeid Latifi-Navid, Hamid Latifi-Navid
Summary: Breast cancer is the most prevalent cancer in females worldwide, with a complex interaction of variables like lifestyle, climate, genetics, and reproductive factors. Long non-coding RNAs (lncRNAs) play important roles in breast cancer development, with their polymorphisms predictive of cancer incidence and useful for early detection and customized therapy. Further large-scale trials and functional assessments are needed to validate the results and shed light on the etiology of breast cancer.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Nutrition & Dietetics
Jankiben R. Patel, Bipika Banjara, Afia Ohemeng, A. Michael Davidson, Stephen M. Boue, Matthew E. Burow, Syreeta L. Tilghman
Summary: Breast cancer cells that become resistant to letrozole overexpress EGFR, MAPK, and HER2, while also acquiring enhanced motility and EMT-like characteristics, which can be attenuated and reversed by glyceollin treatment. Glyceollin inhibits the proliferation and tumor progression of TNBC and estrogen-independent breast cancer cells, but it may not effectively target AI-resistant metastatic breast cancer in clinical settings. Combination therapy of glyceollin and lapatinib induces apoptosis in hormone-dependent AI-resistant breast cancer cells, and it may also be beneficial for letrozole-resistant breast cancer cells by decreasing proliferation and cell cycle progression-associated proteins. This unique opportunity could lead to the development of novel combination therapies for hormone-refractory breast tumors.
Article
Oncology
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman
Summary: This study compared the effectiveness of palbociclib plus letrozole versus letrozole alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer with liver or lung metastasis. The results showed that palbociclib plus letrozole was associated with significantly prolonged progression-free survival and overall survival compared to letrozole alone in all patients. The findings support the use of palbociclib in combination with an aromatase inhibitor as a standard treatment for metastatic breast cancer regardless of visceral disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman
Summary: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. The real-world analysis demonstrated that HR+/HER2- MBC patients were more likely to respond to PAL+LET compared to LET. These findings support the combination as a standard of care for MBC.
Article
Oncology
Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dodson, Vera Martins, Maggie Cheang, Sophie Perry, Chris Holcombe, Nick Turner, Claire Swift, Judith M. Bliss, Stephen Johnston
Summary: In postmenopausal women with ER+/HER2(-) primary breast cancer, higher ER and PgR levels were associated with a greater chance of complete cell-cycle arrest, while higher Ki67, c-PARP, and CCNE1 levels were associated with a lower chance. Letrozole decreased CCND1 levels, but palbociclib showed a tendency to increase them. Ki67 recovery within 3-9 days after stopping palbociclib indicates incomplete suppression of proliferation during the off week.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
G. Jerusalem, S. Farah, A. Courtois, J. Chirgwin, S. Aebi, P. Karlsson, P. Neven, E. Hitre, M. P. Graas, E. Simoncini, E. Abdi, C. Kamby, A. Thompson, S. Loibl, J. Gavila, K. Kuroi, C. Marth, B. Muller, S. O'Reilly, A. Gombos, T. Ruhstaller, H. J. Burstein, M. Rabaglio, B. Ruepp, K. Ribi, G. Viale, R. D. Gelber, A. S. Coates, S. Loi, A. Goldhirsch, M. M. Regan, M. Colleoni
Summary: The study found that extended adjuvant therapy with intermittent administration of letrozole did not improve 7-year disease-free survival compared to continuous treatment, despite the recovery of estrogen levels. Adverse events rates were similar in both groups.
ANNALS OF ONCOLOGY
(2021)
Article
Chemistry, Applied
Iman Akbarzadeh, Anita Saremi Poor, Mohsen Khodarahmi, Mohammadreza Abdihaji, Ali Moammeri, Samaneh Jafari, Zahra Salehi Moghaddam, Mahdi Seif, Maryam Moghtaderi, Zahra Asghari Lalami, Maryam Heydari, Hossein Adelnia, Bahareh Farasati Far
Summary: In this study, the in-silico properties of Gingerol and Letrozole, two potential anti-cancer drugs, were investigated and their ADME drawbacks were predicted. To address these drawbacks, mesoporous silica nanoparticles (MZNGs) were prepared and functionalized, and used as carriers for loading and delivery of the drugs to breast cancer cells. The results showed that the loaded MZNGs effectively inhibited cancer cell proliferation, migration, and invasion through the regulation of gene expression levels. Overall, the Let/Gin-loaded MZNGs demonstrated a suitable and efficient nanosystem for co-delivery of Letrozole and Gingerol with a synergistic effect, offering promise for the treatment of breast cancer and other cancers.
MICROPOROUS AND MESOPOROUS MATERIALS
(2022)
Article
Endocrinology & Metabolism
Alecia Vang, Kelley Salem, Amy M. Fowler
Summary: The objective of this systematic review was to investigate the association between polymorphisms in the progesterone receptor gene (PGR) and breast cancer risk. Forty studies met the eligibility criteria and included 75,032 cases and 89,425 controls. Several PGR polymorphisms were found to be associated with breast cancer risk in some studies, but the overall pooled analysis did not show a significant association. Factors such as age, ethnicity, obesity, and postmenopausal hormone therapy use were reported to contribute to differences in breast cancer risk associated with PGR polymorphisms.
Article
Oncology
Su Jin Heo, Inkyung Jung, Choong-kun Lee, Jee Hung Kim, Sun Min Lim, Yong Wha Moon, Hyo Sup Shim, Jaeheon Jeong, Joo-Hang Kim, Hye Ryun Kim, Byoung Chul Cho
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Review
Oncology
Sun Kyung Baek, Si-Young Kim, Jae-Heon Jeong, Kyung San Cho, Hwi-Joong Yoon
Article
Oncology
Sang Joon Shin, Jae Heon Jeong, Young Suk Park, Kyung Hee Lee, Byoung Yong Shim, Tae Won Kim, Do Youn Oh, Myung Ah Lee, Yong Tai Kim, Yeul Hong Kim, Dae Young Zang, Jae Kyung Roh, Joong Bae Ahn
INVESTIGATIONAL NEW DRUGS
(2011)
Article
Oncology
Jae-Heon Jeong, So-Youn Jung, In Hae Park, Keun Seok Lee, Han-Sung Kang, Seok Won Kim, Youngmee Kwon, Eun A. Kim, Kyung Lan Ko, Byung-Ho Nam, Seeyoun Lee, Jungsil Ro
INVESTIGATIONAL NEW DRUGS
(2012)
Article
Oncology
Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok HyunYoon, Ho-Jin Shin, Yeung-Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung-Soon Jang, Won-Sik Lee, Hwe-Won Lee, HyeonSeok Eom, Jae-sook Ahn, Jae-Heon Jeong, Sun Kyung Baek, Seok Jin Kim, Won Seog Kim, Cheolwon Suh
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2012)
Letter
Medicine, General & Internal
Tae Sung Park, You La Jeon, Hee Joo Lee, Jae-Heon Jeong, Si Young Kim, Eun Hae Cho, Rolf Marschalek, Claus Meyer
JOURNAL OF KOREAN MEDICAL SCIENCE
(2012)
Article
Medicine, General & Internal
Jae-Heon Jeong, Byoung Chul Cho, Hyo Sup Shim, Hye-Ryun Kim, Sun-Min Lim, Se Kyu Kim, Kyung Young Chung, S. M. Bakhtiar Ul Islam, Jae Jin Song, Soo-Youl Kim, Joo Hang Kim
JOURNAL OF KOREAN MEDICAL SCIENCE
(2013)
Article
Oncology
Gun Min Kim, Young Sam Kim, Young Ae Kang, Jae-Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Seung Taek Lim, Joo Hang Kim, Se Kyu Kim, Byoung Chul Cho
JOURNAL OF THORACIC ONCOLOGY
(2012)
Article
Oncology
Se Hyun Kim, Hyo Sup Shim, Jaeho Cho, Jae Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Sang-Jun Ha, Hye Ryun Kim, Hyun Chang, Joo Hang Kim, Crombet Tania, Byoung Chul Cho
Article
Biochemistry & Molecular Biology
Chang-Min Choi, Se-Jin Jang, Seong-Yeol Park, Yong-Bock Choi, Jae-Heon Jeong, Dae-Seok Kim, Hyun-Kyoung Kim, Kang-Seo Park, Byung-Ho Nam, Hyeong-Ryul Kim, Soo-Youl Kim, Kyeong-Man Hong
Article
Oncology
Soojung Hong, Sang Joon Shin, Minkyu Jung, Jaeheon Jeong, Young Joo Lee, Kyoo-Ho Shin, Jae Kyung Roh, Sun Young Rha
Article
Oncology
Jae-Heon Jeong, Sun Min Lim, Ji Young Yun, Gwang Won Rhee, Jae Yun Lim, Jae Yong Cho, Yu Ri Kim
Letter
Medical Laboratory Technology
Sun Young Cho, Jae-Heon Jeong, Woo-In Lee, Juhie Lee, Il Ki Hong, Jin-Tae Suh, Hee Joo Lee, Hwi-Joong Yoon, Tae Sung Park
ANNALS OF LABORATORY MEDICINE
(2013)
Article
Oncology
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
CANCER RESEARCH AND TREATMENT
(2019)